SAS Output

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 313 20% 1376 -181 1158 -400
ERLYTX 76 37 49% 162 86 106 30
GI 476 41 9% 180 -295 207 -269
GU 450 113 25% 496 46 788 338
GYN 57 0 0% 0 -57 0 -57
LEUK 150 19 13% 83 -66 95 -55
LUNG 524 62 12% 272 -251 320 -204
LYMPH 172 2 1% 8 -163 31 -141
MELAN 55 273 496% 1200 1145 885 830
MMYEL 147 19 13% 83 -63 92 -55
OTHER 0 6   26 26 32 32
Total 3665 885   3886 227 3714 49

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   8 8 2 2
BREAST 37 0 0% 0 -37 8 -29
CCD 0 432   1899 1899 1767 1767
GU 0 0   0 0 0 0
LEUK 69 1 1% 4 -64 2 -67
LUNG 43 127 295% 558 515 726 683
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 6   26 26 7 7
PREV 0 14   61 61 55 55
SURV 0 14   61 61 51 51
SXQOL 878 9 1% 39 -838 75 -803
Total 1172 605   2656 1486 2693 1521

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   13 13 3 3
BREAST 1595 313 20% 1376 -218 1166 -429
CCD 0 432   1899 1899 1767 1767
ERLYTX 76 37 49% 162 86 106 30
GI 476 41 9% 180 -295 207 -269
GU 450 113 25% 496 46 788 338
GYN 57 0 0% 0 -57 0 -57
LEUK 219 20 9% 87 -131 97 -122
LUNG 567 189 33% 831 264 1046 479
LYMPH 225 2 1% 8 -216 31 -194
MELAN 55 273 496% 1200 1145 885 830
MMYEL 239 19 8% 83 -155 92 -147
OTHER 0 12   52 52 39 39
PREV 0 14   61 61 55 55
SURV 0 14   61 61 51 51
SXQOL 878 9 1% 39 -838 75 -803
Total 4837 1491   6548 1717 6408 1571

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 125 12% 549 -462 381 -631
ERLYTX 76 30 39% 131 55 99 23
GI 418 38 9% 167 -250 169 -249
GU 375 78 21% 343 -31 520 145
GYN 57 0 0% 0 -57 0 -57
LEUK 122 15 12% 65 -56 86 -36
LUNG 441 41 9% 180 -260 190 -251
LYMPH 129 2 2% 8 -120 28 -101
MELAN 55 143 260% 628 573 469 414
MMYEL 85 19 22% 83 -1 84 -1
OTHER 0 6   26 26 32 32
Total 2770 497   2180 -583 2058 -712

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   8 8 2 2
BREAST 10 0 0% 0 -10 8 -2
CCD 0 424   1864 1864 1759 1759
GU 0 0   0 0 0 0
LEUK 69 1 1% 4 -64 2 -67
LUNG 30 96 320% 422 392 412 382
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 6   26 26 7 7
PREV 0 10   43 43 41 41
SURV 0 11   48 48 30 30
SXQOL 740 9 1% 39 -700 75 -665
Total 994 559   2454 1462 2336 1342

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   13 13 3 3
BREAST 1022 125 12% 549 -472 389 -633
CCD 0 424   1864 1864 1759 1759
ERLYTX 76 30 39% 131 55 99 23
GI 418 38 9% 167 -250 169 -249
GU 375 78 21% 343 -31 520 145
GYN 57 0 0% 0 -57 0 -57
LEUK 191 16 8% 70 -120 88 -103
LUNG 471 137 29% 602 131 602 131
LYMPH 182 2 1% 8 -173 28 -154
MELAN 55 143 260% 628 573 469 414
MMYEL 177 19 11% 83 -93 84 -93
OTHER 0 12   52 52 39 39
PREV 0 10   43 43 41 41
SURV 0 11   48 48 30 30
SXQOL 740 9 1% 39 -700 75 -665
Total 3764 1057   4640 883 4395 631

24-MAR-2017 18:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

23% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 262 403% 1152 1087 1061 996
CCD 0 432   1899 1899 1767 1767
GI 81 3 4% 13 -67 33 -48
GU 215 10 5% 43 -171 38 -177
LEUK 0 1   4 4 23 23
LUNG 53 0 0% 0 -53 1 -52
LYMPH 7 1 14% 4 -2 14 7
MELAN 0 256   1125 1125 815 815
MMYEL 0 19   83 83 75 75
OTHER 0 7   30 30 23 23
PREV 0 14   61 61 55 55
SURV 0 14   61 61 51 51
SXQOL 878 9 1% 39 -838 75 -803
Total 1299 1028   4514 3219 4031 2732

24-MAR-2017 18:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    A011502 ALLIANCE     1      
    EA2133 ECOG-ACR     1      
    NRGGI002 NRG     1      
BREAST II A011203 Breast, Adv, Tam vs Endoxifen ALLIANCE 27JAN2015:00:00:00   6   0.0  
    S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 8 52 333 8.3 Dec-2019
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   33   1.7  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     45      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   23   3.8  
    B51 Breast, Regional Nodal XRT NRG     12      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   15   0.8  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   29   1.2  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   27   1.0  
    S1007 Breast,Adj,N1,Endocrine+/-Chemo SWOG 15JAN2011:00:00:00 74 4795 4000 43.3 Sep-2015
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 42 1145 1900 36.5 Nov-2018
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 4 5 1000 1.2 > 15 Yrs
  OTHER E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   138   0.3  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   7   0.3  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 6 248 3960 41.3 Aug-2024
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 10 32 374 3.7 Dec-2024
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.2  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 2 15 334    
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   37   1.7  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   3   0.2  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   66   7.7  
GI I-II S1313 Panc,Met,mFolfirinox+/-PEGPH20 SWOG 06JAN2014:00:00:00 38 126 172 6.5 Oct-2017
  II E7208 CRC,Adv, Irino/Cet+/-Ramucirumab ECOG-ACRIN 20FEB2014:00:00:00   20   0.5  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   1   0.0  
    S1505 Panc,Resect, Perioperative Chemo SWOG 12OCT2015:00:00:00 17 79 112 2.7 Mar-2018
    S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 SWOG 01SEP2016:00:00:00 6 20 143 3.3 Mar-2020
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   109   2.7  
  III R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II EA8141 UTUC, HG, Chemo then Surg ECOG-ACR 27JAN2015:00:00:00   6   0.3  
    S1314 Blad, COXEN Neoadj. Chemo + Cyst SWOG 11JUL2014:00:00:00 32 169 212 6.3 Sep-2017
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 11 32 180 4.2 Feb-2020
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 1 1 148    
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   2   0.3  
    E2810 Renal, Pazopanib vs Placebo ECOG-ACRIN 17APR2012:00:00:00   46   0.8  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   40   2.2  
    S1011 Blad, Standard vs Extended LND SWOG 01AUG2011:00:00:00 67 618 620 7.2 Mar-2017
    S1216 Pros Adv, ADT +/- TAK-700 or Bic SWOG 01MAR2013:00:00:00 48 1228 1304 19.5 Jun-2017
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 1 2 969    
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 35 34 38 1.3 May-2017
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00 26 28 44 2.3 Sep-2017
  II S0919 Rel AML: Pravastatin+Ida+Ara-C SWOG 15AUG2009:00:00:00 91 115 110 1.0 Nov-2016
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   52   2.5  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   2   0.3  
LUNG I-II 8811 NSCLC, Stage III,ChemoRT+ABT-888 SWOG 02JAN2013:00:00:00 50 35 162 2.2 Jan-2022
  II R1306 NSCLC,Adv,ALK/EGFR,TargetAgents NRG 04NOV2013:00:00:00   8   0.0  
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 1 1 60    
    S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel SWOG 18JUL2016:00:00:00 8 20 53 3.3 Dec-2017
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   1   0.2  
    S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab SWOG 25MAR2015:00:00:00 23 93 605 4.3 Jan-2027
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   16   0.7  
    C140503 NSCL, Lobect v Sublobar resect ALLIANCE 09JUL2007:00:00:00   27   0.2  
    C30607 NSCL,Adv Main Sunitinib v Placbo ALLIANCE     2      
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   50   0.0  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   3   0.0  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   8   1.2  
    S1400I Non-Match: Nivo + Ipi vs Nivo SWOG 18DEC2015:00:00:00 15 178 350 11.7 May-2018
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   264   16.2  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 33 1199   31.2  
LYMPH II 9177 NHL, dose-adj. EPOCH+/-Rituximab NCIMET 13APR2012:00:00:00   19   0.0  
    C51101 CNS, myelo/non-myelo chemo, PhII ALLIANCE 22JUN2012:00:00:00   9   0.5  
MELAN II E3612 MELAN,Adv Ipilimumab±Bevacizumab ECOG-ACR     5      
    S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 32 138 280 4.3 Nov-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 5 1 77 0.2 > 15 Yrs
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   18   1.5  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   15   1.2  
    S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 SWOG 15OCT2015:00:00:00 17 862 1378 80.8 Sep-2017
MMYEL I-II S1211 MM,High Risk, RVD+/-ELO SWOG 27OCT2012:00:00:00   142 110   Jun-2016 Temp Close
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   106   7.7  
    E3A06 AMM, Lenalidomide vs Observation ECOG-ACRIN 08NOV2010:00:00:00   33   0.2  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   2   0.0  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   1   0.0  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.3  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   5   0.0  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   1   0.2  
    AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 COG 02JUL2015:00:00:00   3   0.0  
    E3311 Oroph,Srg + Low or Std IMRT ECOG-ACRIN 01MAR2014:00:00:00   36   0.5  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.2  
    NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo NRG 27OCT2014:00:00:00   1   0.2  
  II-III G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   2   0.3  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   2   0.0  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     4      
    NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG 04FEB2016:00:00:00   4   0.7  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   10   0.2  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   6   1.0  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   2   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 48 133 1488 5.3 > 15 Yrs
  OTHER A211201 Breast Density, MA.32 companion ALLIANCE 22AUG2012:00:00:00   14   0.0  
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   2   0.3  
  OTHER S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 24 68 200 3.8 Jan-2020
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   14   0.2  
    A221102 Brst,AI Arthralgia,Testosterone ALLIANCE 07SEP2012:00:00:00   10   0.7  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

24-MAR-2017 18:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  PREV Y ALLIANCE A211201 Breast Density, MA.32 companion A211201 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II GI N   S1313 Panc,Met,mFolfirinox+/-PEGPH20   N  
  LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N  
  LUNG N   8811 NSCLC, Stage III,ChemoRT+ABT-888   N  
  MMYEL Y SWOG S1211 MM,High Risk, RVD+/-ELO S1211 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
    Y ALLIANCE A011203 Breast, Adv, Tam vs Endoxifen A011203 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 S1513 N  
    Y SWOG S1505 Panc,Resect, Perioperative Chemo S1505 N  
    Y ECOG-ACRIN E7208 CRC,Adv, Irino/Cet+/-Ramucirumab E7208 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
  GU Y SWOG S1314 Blad, COXEN Neoadj. Chemo + Cyst S1314 N  
    Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACR EA8141 UTUC, HG, Chemo then Surg EA8141 N  
  LEUK N   S0919 Rel AML: Pravastatin+Ida+Ara-C   N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel S1507 N  
    Y NRG R1306 NSCLC,Adv,ALK/EGFR,TargetAgents RTOG-1306 N  
  LYMPH Y NCIMET 9177 NHL, dose-adj. EPOCH+/-Rituximab 9177    
    Y ALLIANCE C51101 CNS, myelo/non-myelo chemo, PhII CALGB-51101 Y  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
    Y ECOG-ACR E3612 MELAN,Adv Ipilimumab±Bevacizumab E3612 N  
  OTHER Y ECOG-ACRIN E3311 Oroph,Srg + Low or Std IMRT E3311 Y  
    Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y COG AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 AOST1521 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y NRG NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo NRG-HN002 Y  
II-III ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  LUNG Y SWOG S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab S1403 N  
    Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y SWOG S1007 Breast,Adj,N1,Endocrine+/-Chemo S1007 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
  GU Y SWOG S1011 Blad, Standard vs Extended LND S1011 N  
    Y SWOG S1216 Pros Adv, ADT +/- TAK-700 or Bic S1216 N  
    Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y ECOG-ACRIN E2810 Renal, Pazopanib vs Placebo E2810 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y SWOG S1400I Non-Match: Nivo + Ipi vs Nivo S1400I N  
    Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE C30607 NSCL,Adv Main Sunitinib v Placbo CALGB-30607 Y  
    Y ALLIANCE C140503 NSCL, Lobect v Sublobar resect CALGB-140503    
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  MELAN Y SWOG S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 S1404 Y  
    Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E3A06 AMM, Lenalidomide vs Observation E3A06 Y  
    Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y NRG NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG-GY004 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221102 Brst,AI Arthralgia,Testosterone A221102 Y  
    Y ALLIANCE A011502 A011502    
    Y NRG NRGGI002 NRG-GI002    
    Y ECOG-ACR EA2133 EA2133    

24-MAR-2017 18:10

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 1488 Y-03/01/13 48 133 133 64 > 15 Yrs > 15 Yrs
S1007 S1007 Breast,Adj,N1,Endocrine+/-Chemo (BREAST) 4000 Y-01/15/11 74 4795 4795 520 Sep-2015 4.7
S1011 S1011 Blad, Standard vs Extended LND (GU) 620 Y-08/01/11 67 618 618 86 Mar-2017 5.6
S1207 S1207 Brst,Adj,Endocrine+/-Everolimus (BREAST) 1900 Y-09/03/13 42 1145 1145 438 Nov-2018 5.2
S1216 S1216 Pros Adv, ADT +/- TAK-700 or Bic (GU) 1304 Y-03/01/13 48 1228 1228 234 Jun-2017 4.3
S1222 Brst,Fulv. +/- Ever. +/- Anastr. (BREAST) 840 T-05/09/14 34 37 37 0 > 15 Yrs > 15 Yrs
S1400I S1400I Non-Match: Nivo + Ipi vs Nivo (LUNG) 350 Y-12/18/15 15 178 178 140 May-2018 2.4
S1403 S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG) 605 Y-03/25/15 23 93 93 52 Jan-2027 11.8
S1404 S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN) 1378 Y-10/15/15 17 862 862 970 Sep-2017 1.9
S1415CD S1415CD TrACER CSF Standing Order Intervention for FN (CCD) 3960 Y-09/01/16 6 248 248 496 Aug-2024 8.0
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 4 5 5 13.905788 > 15 Yrs > 15 Yrs
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 1 2 2      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.